Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel Free ZBIO Stock Alerts

Zenas BioPharma (ZBIO) Financials

Zenas BioPharma logo
$25.16 -1.24 (-4.70%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$25.28 +0.11 (+0.46%)
As of 10/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Zenas BioPharma

Annual Income Statements for Zenas BioPharma

This table shows Zenas BioPharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -37 -157 -378
Consolidated Net Income / (Loss)		 -37 -157 -378
Net Income / (Loss) Continuing Operations		 -37 -157 -378
Total Pre-Tax Income 		-37 -157 -378
Total Operating Income		 -37 -164 -383
Total Gross Profit		 50 5.00 10
Total Revenue		 50 5.00 10
Operating Revenue		 50 5.00 10
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 87 169 393
Selling, General & Admin Expense		 17 30 53
Research & Development Expense		 70 139 340
Total Other Income / (Expense), net		 0.32 7.33 5.24
Interest Expense		 - 0.00 7.33
Interest & Investment Income		 - 7.97 12
Other Income / (Expense), net		 0.32 -0.64 0.42
Income Tax Expense		 0.30 0.43 -0.08
Basic Earnings per Share		 ($24.25) ($11.89) ($8.44)
Weighted Average Basic Shares Outstanding		 1.53M 13.20M 44.73M
Diluted Earnings per Share		 ($24.25) ($11.89) ($8.44)
Weighted Average Diluted Shares Outstanding		 1.53M 13.20M 44.73M
Weighted Average Basic & Diluted Shares Outstanding		 - 41.80M 57.36M

Quarterly Income Statements for Zenas BioPharma

This table shows Zenas BioPharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 36 -28 -38 -39 -53 -34 -52 -51 -240 -81 -111
Consolidated Net Income / (Loss)		 36 -28 -38 -39 -53 -34 -52 -51 -240 -81 -111
Net Income / (Loss) Continuing Operations		 36 -28 -38 -39 -53 -34 -52 -51 -240 -81 -111
Total Pre-Tax Income 		36 -28 -38 -39 -52 -34 -52 -51 -240 -81 -111
Total Operating Income		 36 -28 -40 -41 -56 -37 -55 -53 -238 -77 -108
Total Gross Profit		 50 0.00 0.00 0.00 5.00 10 0.00 0.00 - 0.00 1.00
Total Revenue		 50 0.00 0.00 0.00 5.00 10 0.00 0.00 - 0.00 1.00
Operating Revenue		 50 0.00 0.00 0.00 5.00 10 0.00 0.00 - 0.00 1.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 14 28 40 41 61 47 55 53 238 77 109
Selling, General & Admin Expense		 5.02 4.93 5.90 7.45 11 12 12 13 16 17 16
Research & Development Expense		 9.35 23 34 34 49 35 43 39 222 60 93
Total Other Income / (Expense), net		 -0.02 -0.22 1.88 2.38 3.30 3.55 2.96 1.08 -2.35 -3.64 -3.68
Interest Expense		 - - - - - 0.00 0.00 - - 6.63 10
Interest & Investment Income		 - - - - - 3.39 2.74 - - 3.02 6.60
Other Income / (Expense), net		 -0.02 -0.22 1.88 2.38 -4.68 0.16 0.22 1.08 -7.18 -0.02 0.02
Income Tax Expense		 - 0.00 0.00 0.00 0.43 -0.21 0.02 0.00 0.11 0.00 0.11
Basic Earnings per Share		 $2.42 ($17.89) ($24.23) ($5.02) $35.25 ($0.80) ($1.25) ($1.22) ($5.17) ($1.46) ($1.77)
Weighted Average Basic Shares Outstanding		 1.54M 1.55M 1.57M 7.70M 13.20M 41.80M 41.87M 42.16M 44.73M 55.62M 63.11M
Diluted Earnings per Share		 $1.96 ($17.89) ($24.23) ($5.02) $35.25 ($0.80) ($1.25) ($1.22) ($5.17) ($1.46) ($1.77)
Weighted Average Diluted Shares Outstanding		 1.90M 1.55M 1.57M 7.70M 13.20M 41.80M 41.87M 42.16M 44.73M 55.62M 63.11M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 41.79M 41.80M 41.83M 42.11M 53.68M 57.36M 63.13M 65.18M

Annual Cash Flow Statements for Zenas BioPharma

This table details how cash moves in and out of Zenas BioPharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -10 263 -209
Net Cash From Operating Activities		 -31 -120 -172
Net Cash From Continuing Operating Activities		 -31 -120 -172
Net Income / (Loss) Continuing Operations		 -37 -157 -378
Consolidated Net Income / (Loss)		 -37 -157 -378
Depreciation Expense		 0.11 0.14 0.06
Amortization Expense		 0.00 -0.60 -1.93
Non-Cash Adjustments To Reconcile Net Income		 14 12 205
Changes in Operating Assets and Liabilities, net		 -7.33 26 1.85
Net Cash From Investing Activities		 -0.02 -31 -252
Net Cash From Continuing Investing Activities		 -0.02 -31 -252
Purchase of Property, Plant & Equipment		 -0.02 -0.13 -0.02
Purchase of Investments		 0.00 -36 -418
Sale and/or Maturity of Investments		 0.00 6.00 201
Other Investing Activities, net		 - 0.00 -35
Net Cash From Financing Activities		 20 413 215
Net Cash From Continuing Financing Activities		 20 413 215
Repurchase of Common Equity		 0.00 -6.33 -13
Issuance of Debt		 20 0.00 75
Issuance of Preferred Equity		 0.00 178 0.00
Issuance of Common Equity		 0.00 241 149
Other Financing Activities, net		 0.12 0.28 4.10
Effect of Exchange Rate Changes		 0.08 0.16 -0.25

Quarterly Cash Flow Statements for Zenas BioPharma

This table details how cash moves in and out of Zenas BioPharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -15 -20 147 176 -40 -123 -153 72 -4.92 390 -304
Net Cash From Operating Activities		 -15 -19 -31 -31 -39 -37 -42 -41 -52 -75 -57
Net Cash From Continuing Operating Activities		 -15 -19 -31 -31 -39 -37 -42 -41 -52 -75 -57
Net Income / (Loss) Continuing Operations		 -25 -28 -38 -39 -53 -34 -52 -51 -240 -81 -111
Consolidated Net Income / (Loss)		 -25 -28 -38 -39 -53 -34 -52 -51 -240 -81 -111
Depreciation Expense		 0.03 0.03 0.04 0.04 0.03 0.02 0.01 0.01 0.01 0.01 0.00
Amortization Expense		 - 0.00 - - - -0.38 -0.94 -0.19 -0.42 -0.11 -1.29
Non-Cash Adjustments To Reconcile Net Income		 1.44 1.64 1.69 2.84 5.51 5.52 6.13 14 180 16 48
Changes in Operating Assets and Liabilities, net		 7.72 7.03 5.30 4.67 9.11 -8.64 5.38 -3.45 8.56 -9.65 7.71
Net Cash From Investing Activities		 -0.02 -0.02 -0.04 -27 -3.74 -86 -112 40 -93 32 -288
Net Cash From Continuing Investing Activities		 -0.02 -0.02 -0.04 -27 -3.74 -86 -112 40 -93 32 -288
Purchase of Investments		 - 0.00 - -27 -9.66 -99 -127 -59 -133 -77 -332
Sale and/or Maturity of Investments		 - 0.00 - - - 13 14 104 70 108 74
Net Cash From Financing Activities		 0.05 -0.61 178 234 1.85 0.10 1.72 73 141 433 42
Net Cash From Continuing Financing Activities		 0.05 -0.61 178 234 1.85 0.10 1.72 73 141 433 42
Repayment of Debt		 - - - - - 0.00 - - - -0.47 -1.46
Issuance of Debt		 - - - - - 0.00 - - - 268 29
Issuance of Common Equity		 - 0.00 - 234 6.25 0.00 - 0.28 149 166 14
Other Financing Activities, net		 0.05 0.04 0.12 0.03 0.08 0.10 1.72 -2.66 4.94 0.37 0.81
Effect of Exchange Rate Changes		 -0.09 0.04 0.03 -0.05 0.14 -0.05 -0.24 0.03 0.01 -0.31 -0.76

Annual Balance Sheets for Zenas BioPharma

This table presents Zenas BioPharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 68 370 384
Total Current Assets		 60 356 351
Cash & Equivalents		 57 320 111
Short-Term Investments		 0.00 31 233
Prepaid Expenses		 2.95 5.07 7.98
Plant, Property, & Equipment, net		 0.19 0.19 0.03
Total Noncurrent Assets		 8.18 14 32
Long-Term Investments		 - 0.00 17
Other Noncurrent Operating Assets		 8.18 14 15
Total Liabilities & Shareholders' Equity		 68 370 384
Total Liabilities		 44 58 141
Total Current Liabilities		 23 57 63
Accounts Payable		 5.40 17 7.11
Accrued Expenses		 17 39 54
Other Current Liabilities		 0.56 0.79 1.12
Total Noncurrent Liabilities		 21 0.22 79
Long-Term Debt		 20 0.00 0.00
Other Noncurrent Operating Liabilities		 0.26 0.22 79
Total Equity & Noncontrolling Interests		 -226 312 242
Total Preferred & Common Equity		 -226 312 242
Total Common Equity		 -226 312 242
Common Stock		 4.65 700 1,007
Retained Earnings		 -230 -387 -765
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.19 -0.06

Quarterly Balance Sheets for Zenas BioPharma

This table presents Zenas BioPharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 403 334 293 322 748 702
Total Current Assets		 394 318 279 297 730 654
Cash & Equivalents		 360 197 44 116 500 197
Short-Term Investments		 27 116 229 175 217 447
Prepaid Expenses		 6.98 5.43 5.32 5.76 13 11
Plant, Property, & Equipment, net		 0.15 0.07 0.06 0.05 0.03 0.02
Total Noncurrent Assets		 9.51 16 14 25 17 48
Long-Term Investments		 - 1.84 1.61 11 1.34 31
Other Noncurrent Operating Assets		 9.51 14 13 15 16 17
Total Liabilities & Shareholders' Equity		 403 334 293 322 748 702
Total Liabilities		 44 49 53 126 412 455
Total Current Liabilities		 44 49 53 52 61 66
Accounts Payable		 15 20 7.93 6.44 8.94 7.59
Accrued Expenses		 29 28 45 45 51 57
Other Current Liabilities		 0.38 0.91 0.79 0.62 1.04 0.82
Total Noncurrent Liabilities		 0.00 0.32 0.22 73 351 389
Long-Term Debt		 0.00 - - 73 266 297
Other Noncurrent Operating Liabilities		 0.00 0.32 0.22 0.18 85 92
Total Equity & Noncontrolling Interests		 359 284 240 196 336 247
Total Preferred & Common Equity		 359 284 240 196 336 247
Total Common Equity		 359 284 240 196 336 247
Common Stock		 694 705 713 721 1,182 1,206
Retained Earnings		 -335 -421 -473 -525 -846 -958
Accumulated Other Comprehensive Income / (Loss)		 0.05 0.14 -0.09 -0.07 -0.38 -1.14

Annual Metrics And Ratios for Zenas BioPharma

This table displays calculated financial ratios and metrics derived from Zenas BioPharma's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 53,679,166.00
DEI Adjusted Shares Outstanding		 - - 53,679,166.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -7.04
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -26 -115 -268
Return On Investment Capital (ROIC_SIMPLE)		 12.66% -36.72% -83.59%
Earnings before Interest and Taxes (EBIT)		 -37 -164 -383
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 -164 -385
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -89 -267
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 -12 -38 -40
Increase / (Decrease) in Invested Capital		 0.00 -26 -1.29
Book Value per Share		 ($147.42) $7.48 $4.51
Tangible Book Value per Share		 ($147.42) $7.48 $4.51
Total Capital		 45 312 321
Total Debt		 20 0.00 79
Total Long-Term Debt		 20 0.00 79
Net Debt		 -37 -351 -282
Capital Expenditures (CapEx)		 0.02 0.13 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -52 -55
Debt-free Net Working Capital (DFNWC)		 37 299 289
Net Working Capital (NWC)		 37 299 289
Net Nonoperating Expense (NNE)		 11 42 110
Net Nonoperating Obligations (NNO)		 -37 -351 -282
Total Depreciation and Amortization (D&A)		 0.11 -0.47 -1.88
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($11.89) ($8.44)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 13.20M 44.73M
Adjusted Diluted Earnings per Share		 $0.00 ($11.89) ($8.44)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 13.20M 44.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 41.80M 57.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -115 -268
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Zenas BioPharma

This table displays calculated financial ratios and metrics derived from Zenas BioPharma's official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - 0.00 0.00 - 41,791,037.00 41,799,336.00 41,834,182.00 42,110,313.00 53,679,166.00 57,361,260.00 63,133,377.00
DEI Adjusted Shares Outstanding		 - 0.00 0.00 - 41,791,037.00 41,799,336.00 41,834,182.00 42,110,313.00 53,679,166.00 57,361,260.00 63,133,377.00
DEI Earnings Per Adjusted Shares Outstanding		 - 0.00 0.00 - -1.26 -0.80 -1.25 -1.22 -4.48 -1.41 -1.77
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% - 0.00% 0.00% 0.00% - -100.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% -208.42% - -22.94% -40.58% -33.99% - -106.44% -94.97%
EBIT Growth		 0.00% 0.00% 0.00% -208.42% - -21.50% -38.01% -33.40% - -108.15% -95.91%
NOPAT Growth		 0.00% 0.00% 0.00% -180.53% - -35.36% -38.94% -28.29% - -107.21% -95.17%
Net Income Growth		 0.00% 0.00% 0.00% -208.42% - -20.77% -37.51% -33.40% - -141.23% -113.42%
EPS Growth		 0.00% 0.00% 0.00% -356.12% - 95.53% 94.84% 75.70% - -82.50% -41.60%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% - -93.96% -34.83% -32.41% - -102.95% -37.12%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% -2,314.40% - 775.17% 672.07%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% -17.61% - -291.35% -267.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -100.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -36.10% 0.00% - 0.00% -55.63% 2.72% - 68.45% -40.59%
EBIT Q/Q Growth		 0.00% 0.00% -36.06% 0.00% - 0.00% -54.55% 1.35% - 68.44% -39.12%
NOPAT Q/Q Growth		 0.00% 0.00% -43.96% 0.00% - 0.00% -47.77% 4.68% - 67.50% -39.18%
Net Income Q/Q Growth		 0.00% 0.00% -36.61% 0.00% - 0.00% -55.55% 1.39% - 66.32% -37.62%
EPS Q/Q Growth		 0.00% 0.00% -35.44% 0.00% - 0.00% -56.25% 2.40% - 71.76% -21.23%
Operating Cash Flow Q/Q Growth		 0.00% -24.04% -62.07% 0.00% - 3.90% -12.66% 1.48% - -43.47% 23.88%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -188.88% -855.63% - 138.03% -41.90%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -17.96% 8.74% - 1.11% -10.92%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% - 100.00% 0.00% 0.00% - 0.00% 100.00%
EBITDA Margin		 71.22% 0.00% 0.00% 0.00% - -341.37% 0.00% 0.00% - 0.00% -10,892.60%
Operating Margin		 71.25% 0.00% 0.00% 0.00% - -373.30% 0.00% 0.00% - 0.00% -10,765.90%
EBIT Margin		 71.22% 0.00% 0.00% 0.00% - -337.78% 0.00% 0.00% - 0.00% -10,764.30%
Profit (Net Income) Margin		 71.22% 0.00% 0.00% 0.00% - -335.73% 0.00% 0.00% - 0.00% -11,145.60%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% - 99.39% 100.04% 100.00% - 100.00% 100.10%
Interest Burden Percent		 100.00% 100.00% 100.40% 100.00% - 100.00% 100.00% 100.00% - 104.67% 103.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% - -57.25% -73.87% -68.33% - -137.11% -199.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% - -15.18% 0.00% 0.00% - 0.00% -21.64%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% - -15.09% 0.00% 0.00% - 0.00% -22.41%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% - -57.25% -73.87% -68.33% - -137.11% -199.04%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% - -57.25% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 36 -19 -28 -29 -39 -26 -39 -37 -167 -54 -75
NOPAT Margin		 71.25% 0.00% 0.00% 0.00% - -261.31% 0.00% 0.00% - 0.00% -7,536.13%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -5.13% - -4.74% -9.90% -4.78% - -7.00% -11.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -12.46% -9.19% -16.11% -13.66% -51.93% -9.00% -13.85%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 10.05% 0.00% 0.00% 0.00% - 124.15% 0.00% 0.00% - 0.00% 1,574.60%
R&D to Revenue		 18.70% 0.00% 0.00% 0.00% - 349.15% 0.00% 0.00% - 0.00% 9,291.30%
Operating Expenses to Revenue		 28.75% 0.00% 0.00% 0.00% - 473.30% 0.00% 0.00% - 0.00% 10,865.90%
Earnings before Interest and Taxes (EBIT)		 36 -28 -38 -39 -60 -34 -52 -51 -245 -77 -108
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 36 -28 -38 -39 -61 -34 -53 -52 -246 -77 -109
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.36 - 1.16 1.69 4.76 - 3.24 6.48
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.36 - 1.16 1.69 4.76 - 3.24 6.48
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 - 22.02 27.05 62.40 - 0.00 1,601.79
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 - 1.07 8.72 47.16 - 0.00 1,224.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.37 - 0.79 1.20
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.37 - 0.79 1.20
Financial Leverage		 0.00 0.00 0.00 -1.08 - -1.11 -1.15 -1.11 - -1.24 -1.34
Leverage Ratio		 0.00 0.00 0.00 1.12 - 1.17 1.22 1.31 - 1.74 2.04
Compound Leverage Factor		 0.00 0.00 0.00 1.12 - 1.17 1.22 1.31 - 1.83 2.11
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 27.09% - 44.17% 54.59%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 27.09% - 44.17% 54.59%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% - 100.00% 100.00% 72.91% - 55.83% 45.41%
Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 -0.36 - -0.63 -0.62
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 1.13 - 1.07 0.79
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 -0.36 - -0.63 -0.62
Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 -0.52 - -0.90 -0.89
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 1.63 - 1.53 1.13
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 -0.52 - -0.90 -0.89
Altman Z-Score		 0.00 0.00 0.00 0.00 - 2.92 2.68 2.62 - 0.73 0.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 8.95 - 6.47 5.23 5.66 - 11.94 9.93
Quick Ratio		 0.00 0.00 0.00 8.79 - 6.36 5.13 5.55 - 11.73 9.77
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -1.32 0.00 3.77 -3.35 -32 -165 33 19
Operating Cash Flow to CapEx		 0.00% -86,827.27% -88,454.29% 0.00% - -205,838.89% 0.00% 0.00% - -3,759,800.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 4.97 1.86
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -11.34 -5.56
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -11.34 -5.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 - 0.04 0.05 0.04 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 - 208.33 245.90 153.06 - 0.00 23.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -27 -38 -30 -35 -32 -40 -117 -130
Invested Capital Turnover		 0.00 0.00 0.00 0.00 - -1.00 -0.85 -0.50 - 0.00 -0.01
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -27 0.00 -30 -35 -4.82 -1.29 -87 -95
Enterprise Value (EV)		 0.00 0.00 0.00 -257 - 16 131 707 - 635 1,225
Market Capitalization		 225 225 225 130 - 330 406 936 - 1,087 1,602
Book Value per Share		 $0.00 $0.00 $0.00 $46.69 $7.48 $6.80 $5.73 $4.66 $4.51 $5.85 $3.91
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $46.69 $7.48 $6.80 $5.73 $4.66 $4.51 $5.85 $3.91
Total Capital		 0.00 0.00 0.00 359 312 284 240 269 321 602 544
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73 79 266 297
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73 79 266 297
Net Debt		 0.00 0.00 0.00 -387 -351 -314 -275 -229 -282 -453 -377
Capital Expenditures (CapEx)		 0.00 0.02 0.04 0.00 0.07 0.02 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -37 -52 -44 -48 -47 -55 -48 -55
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 350 299 269 225 244 289 669 588
Net Working Capital (NWC)		 0.00 0.00 0.00 350 299 269 225 244 289 669 588
Net Nonoperating Expense (NNE)		 0.02 8.50 10 9.92 14 7.44 14 15 74 27 36
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -387 -351 -314 -275 -229 -282 -453 -377
Total Depreciation and Amortization (D&A)		 0.00 0.03 0.04 0.00 -0.57 -0.36 -0.92 -0.18 -0.41 -0.10 -1.28
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - -291.36% -319.47% -311.09% - 0.00% -5,515.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 1,791.17% 1,502.39% 1,628.14% - 0.00% 58,797.60%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 1,791.17% 1,502.39% 1,628.14% - 0.00% 58,797.60%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($5.02) $35.25 ($0.80) ($1.25) ($1.22) ($5.17) ($1.46) ($1.77)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 7.70M 13.20M 41.80M 41.87M 42.16M 44.73M 55.62M 63.11M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($5.02) $35.25 ($0.80) ($1.25) ($1.22) ($5.17) ($1.46) ($1.77)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 7.70M 13.20M 41.80M 41.87M 42.16M 44.73M 55.62M 63.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 41.79M 41.80M 41.83M 42.11M 53.68M 57.36M 63.13M 65.18M
Normalized Net Operating Profit after Tax (NOPAT)		 25 -19 -28 -29 -39 -26 -39 -37 -167 -54 -75
Normalized NOPAT Margin		 49.87% 0.00% 0.00% 0.00% - -261.31% 0.00% 0.00% - 0.00% -7,536.13%
Pre Tax Income Margin		 71.22% 0.00% 0.00% 0.00% - -337.78% 0.00% 0.00% - 0.00% -11,134.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -11.67 -10.45
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -8.17 -7.32
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -11.67 -10.45
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - -8.17 -7.32
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% - -3.49% -2.78% -2.36% - -2.99% 0.00%

Financials Breakdown Chart

Key Financial Trends

Zenas BioPharma remains a development-stage biotech with substantial liquidity, but it continues to report significant operating losses and cash burn. The company generated $1.0 million of revenue in Q2 2026, compared with no revenue in Q1 2026 and $10.0 million in Q1 2025. Revenue remains inconsistent and is not yet sufficient to support the business.

  • Large liquidity position: Cash, short-term investments and long-term investments totaled approximately $673.9 million at June 30, 2026. This provides a meaningful funding base for clinical development and operations.
  • Strong short-term balance-sheet coverage: Current assets of $653.8 million compared with current liabilities of $65.8 million imply a current ratio of roughly 9.9, indicating substantial near-term liquidity.
  • Quarterly operating cash burn improved sequentially: Net cash used in operating activities declined to $57.2 million in Q2 2026 from $75.2 million in Q1 2026, although it remained higher than the $41.7 million used in Q2 2025.
  • Investment income is helping offset expenses: Interest and investment income increased to $6.6 million in Q2 2026 from $3.0 million in Q1 2026, reflecting the company’s larger investment portfolio.
  • Investment portfolio composition changed significantly: Short-term investments increased to $446.5 million from $217.0 million in Q1 2026, while cash fell to $196.6 million from $500.2 million. This appears to reflect treasury management and investment purchases rather than a direct loss of liquidity.
  • Liquidity could support operations for several years at the latest quarterly burn rate: Total cash and investments were approximately 11.8 times Q2 operating cash use. However, this is only an illustration; clinical spending, milestone payments and financing conditions could materially change the runway.
  • Operating losses continue to widen: Q2 2026 operating expenses rose to $108.7 million from $77.4 million in Q1 2026 and $55.2 million in Q2 2025. Research and development expense was the main driver at $92.9 million.
  • Net loss remained substantial: Zenas reported a $111.5 million net loss, or a diluted loss of $1.77 per share, in Q2 2026. The company has reported losses in each provided quarter since Q2 2024, aside from a profit reported in Q3 2023.
  • Debt has increased materially: Long-term debt reached $297.0 million at June 30, 2026, up from $265.7 million in Q1 2026 and zero in Q2 2025. Interest expense also rose to $10.3 million in Q2 2026, exceeding interest and investment income.
  • Shareholder dilution remains a risk: Weighted-average basic shares increased to 63.1 million in Q2 2026 from 55.6 million in Q1 2026 and 41.9 million in Q2 2025. The company has relied on equity issuance, along with debt financing, to fund its cash needs.

Overall, Zenas’ balance sheet provides a meaningful cushion for continued drug development, and its liquid assets substantially exceed its debt. However, the company remains dependent on external financing or future product and partnership revenue because research spending, operating losses and debt obligations continue to consume capital. Investors should monitor clinical progress, revenue consistency, additional financing activity and whether quarterly cash burn begins to moderate.

10/14/26 03:36 AM ETAI Generated. May Contain Errors.

Zenas BioPharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zenas BioPharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Zenas BioPharma's net income appears to be on a downward trend, with a most recent value of -$377.74 million in 2025, falling from -$37.12 million in 2023. The previous period was -$156.99 million in 2024. See where experts think Zenas BioPharma is headed by visiting Zenas BioPharma's forecast page.

Zenas BioPharma's total operating income in 2025 was -$383.06 million, based on the following breakdown:
  • Total Gross Profit: $10 million
  • Total Operating Expenses: $393.06 million

Over the last 2 years, Zenas BioPharma's total revenue changed from $50 million in 2023 to $10 million in 2025, a change of -80.0%.

In the past 7 quarters, Zenas BioPharma's cash and equivalents has ranged from $44.01 million in Q2 2025 to $500.22 million in Q1 2026, and is currently $196.58 million as of their latest financial filing in Q2 2026.

Zenas BioPharma had total debt of $78.64 million at the end of 2025, compared with none in 2024, and a 287.4% increase since 2023.

Over the last 2 years, Zenas BioPharma's book value per share changed from -147.42 in 2023 to 4.51 in 2025.


Related Companies

Financial statements for NASDAQ:ZBIO last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
This little-known gold fund distributes cash every Friday
Gold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...
Investors Alley | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel